MedPage Today on MSN

PSMA-PET cuts need for biopsy in suspected prostate cancer

But does it cost too much?
InvestorsHub on MSN

Pfizer’s TALZENNA combination shows progress against prostate cancer

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Weighing Pros And Cons Of Prostate Cancer Blood Tests

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...
Healio

FDA approves new formulation of PET imaging agent for prostate cancer

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
Pharmabiz

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer

Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

MyMichigan Sault now offers advanced prostate cancer detection scans

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Masked T‑cell engagers: Cancer immunotherapies for the future?

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...